SELLAS Life Sciences shares rose in premarket trading Wednesday amid increased institutional ownership and anticipation of clinical trial results.
The company is nearing the final analysis of its Phase 3 REGAL trial of galinpepimut-S, a cancer vaccine for acute myeloid leukemia (AML). Initial top-line data from a Phase 2 trial of SLS009 in newly diagnosed AML patients is expected in the fourth quarter of 2026.
Gamma Investing and Everhart have increased their buying of SELLAS shares. Johnson & Johnson’s stated interest in oncology acquisitions has also drawn attention to smaller companies in the sector, including SELLAS.